Tandem Diabetes Care Inc

TNDM: XNAS (USA)
View Stock Summary
Morningstar Rating for StocksFair ValueEconomic MoatCapital Allocation
g>LOCK|>%YLOCK|#m#mh&y

Tandem Diabetes Earnings: New Shift to Focus on Pharmacy Channel Could Increase Adoption

Tandem reported fourth-quarter results that featured impressive US pump sales growth of 13% and 11% growth in international pump sales. Also, the firm is embarking on a major effort to shift to the pharmacy channel and a pay-as-you-go model in 2026.

Sponsor Center